SOPHiA GENETICS®

Presents

SOPHiA DDM®

SaaS Analytics Platform for Clinical Genomics

Clinicians Platform of Choice for Genomic Testing

Patients

Hospitals

SOPHiA DDM

Ensure Top Analytical Performance

Exclusively available on SOPHiA DDM, SOPHiA, the collective Artificial Intelligence (AI) for Data-Driven Medicine, detects, annotates and pre-classifies genomic variants, to help clinicians better diagnose and treat patients.

SOPHiA™

Respect Patient Privacy

SOPHiA DDM encrypts all data to the highest industry standards before storing it redundantly in secured and private data centers. The platform ensures patient privacy and respects EU Directives and National Privacy Laws.

bsi.
ISO 13485
Medical Devices Quality Management

ISO/IEC 27001
Information Security Management

Access to SOPHiA's Community

SOPHiA GENETICS has built the World's Largest Clinical Genomics Community with hundreds of institutions participating in the democratization of Data-Driven Medicine. Through SOPHiA DDM, thousands of experts can easily interpret the variants and flag them with the appropriate level of pathogenicity. This highly valuable information feeds the variant knowledge base and is anonymously and safely shared among the members of the community.

Benefits

Fast turnaround time: data ready in 2 hours

Top analytical performance

Secure data storage and encryption

info@sophiagenetics.com

sophiagenetics.com

SOPHiA DDM®

Intuitive Workflow & User-Friendly Interface

1 Login

Access the platform securely

2 Request Creation

- Load your raw DNA sequence files
- SOPHiA DDM encrypts and processes the data

3 Data Analysis & Interpretation

- Automated quality check, alignment and variant calling
- Automatic and comprehensive variant annotation (multiple sources)
- Pre-classification of variants in different pathogenicity classes
- Variant filtering
- Facilitated interpretation through integrated databases

4 Variant Report

Establish your own variant report

OncoPortal™

Get Actionable Information to Fight Cancer

For biologists and clinicians working on solid tumors and haematological malignancies, the OncoPortal interface provides comprehensive annotations of genome-wide associations among human gene variants, disease, and drug treatment. It is based on precision medicine intelligence with curated and reliable databases on gene biomarkers and clinical trials.

1

EGFR — p.Thr790Met
Missense mutation
VF: 50.38% depth: 2356

2

Sensitive
Osimertinib mesylate — Therapeutic agent
Carcinoma, Non-Small-Cell Lung

3

Summary:
EGFR c.2369C>T is a missense mutation in codon 790 yielding a threonine-to-methionine (T790M) amino acid change (J Thorac Oncol 2013, 8(1): 45-51). EGFR is mutated in approximately 12% of non-small cell lung ...
Clinical Trial(s): 29

Somatic classification based on variant-disease-drug association linked to the patient's tumor profile

Specific drug association with the disease and its effect in terms of sensitivity for each patient

Clinical evidence summary including known effects of each association on the disease and its treatment

---

info@sophiagenetics.com

sophiagenetics.com